Bavarian Nordic A/S (BVNRY)
11.34
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
Bavarian Nordic Research and Development Expense (Quarterly) : 25.43M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.43M |
| March 31, 2026 | 27.43M |
| December 31, 2025 | 28.32M |
| September 30, 2025 | 20.86M |
| June 30, 2025 | 44.55M |
| March 31, 2025 | 24.28M |
| December 31, 2024 | 29.11M |
| September 30, 2024 | 38.91M |
| June 30, 2024 | 30.25M |
| March 31, 2024 | 26.95M |
| December 31, 2023 | 64.35M |
| September 30, 2023 | 143.06M |
| June 30, 2023 | 73.58M |
| March 31, 2023 | 42.96M |
| December 31, 2022 | 73.13M |
| September 30, 2022 | 48.73M |
| June 30, 2022 | 26.45M |
| March 31, 2022 | 15.80M |
| December 31, 2021 | 16.20M |
| September 30, 2021 | 11.81M |
| June 30, 2021 | 15.74M |
| March 31, 2021 | 19.78M |
| December 31, 2020 | 18.43M |
| September 30, 2020 | 16.06M |
| June 30, 2020 | 8.561M |
| Date | Value |
|---|---|
| March 31, 2020 | 9.744M |
| December 31, 2019 | 17.92M |
| September 30, 2019 | 13.59M |
| June 30, 2019 | 14.05M |
| March 31, 2019 | 15.78M |
| December 31, 2018 | 16.77M |
| September 30, 2018 | 11.22M |
| June 30, 2018 | 14.08M |
| March 31, 2018 | 19.25M |
| December 31, 2017 | 22.53M |
| September 30, 2017 | 21.77M |
| June 30, 2017 | 12.35M |
| March 31, 2017 | 12.22M |
| December 31, 2016 | 15.69M |
| September 30, 2016 | 13.92M |
| June 30, 2016 | 13.52M |
| March 31, 2016 | 15.39M |
| December 31, 2015 | 13.20M |
| September 30, 2015 | 11.54M |
| June 30, 2015 | 13.27M |
| March 31, 2015 | 17.52M |
| December 31, 2014 | 24.39M |
| September 30, 2014 | 20.29M |
| June 30, 2014 | 17.71M |
| March 31, 2014 | 14.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Evaxion AS | 2.331M |
| Genmab A/S | 458.35M |
| Ascendis Pharma A/S | 85.39M |
| Zealand Pharma A/S | 80.28M |
| Agenus, Inc. | 14.76M |